- Home
- CCTG vs IMNN Comparison
CCTG vs IMNN Comparison
Compare CCTG & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCTG
- IMNN
- Stock Information
- Founded
- CCTG 1993
- IMNN 1982
- Country
- CCTG Hong Kong
- IMNN United States
- Employees
- CCTG N/A
- IMNN N/A
- Industry
- CCTG
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- CCTG
- IMNN Health Care
- Exchange
- CCTG Nasdaq
- IMNN Nasdaq
- Market Cap
- CCTG 14.9M
- IMNN 12.1M
- IPO Year
- CCTG 2024
- IMNN 1985
- Fundamental
- Price
- CCTG $1.06
- IMNN $0.77
- Analyst Decision
- CCTG
- IMNN Buy
- Analyst Count
- CCTG 0
- IMNN 2
- Target Price
- CCTG N/A
- IMNN $14.00
- AVG Volume (30 Days)
- CCTG 5.9K
- IMNN 5.4M
- Earning Date
- CCTG 08-23-2025
- IMNN 08-13-2025
- Dividend Yield
- CCTG N/A
- IMNN N/A
- EPS Growth
- CCTG N/A
- IMNN N/A
- EPS
- CCTG N/A
- IMNN N/A
- Revenue
- CCTG $16,463,490.00
- IMNN N/A
- Revenue This Year
- CCTG N/A
- IMNN N/A
- Revenue Next Year
- CCTG N/A
- IMNN N/A
- P/E Ratio
- CCTG N/A
- IMNN N/A
- Revenue Growth
- CCTG 3.27
- IMNN N/A
- 52 Week Low
- CCTG $0.99
- IMNN $0.37
- 52 Week High
- CCTG $3.17
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- CCTG 39.49
- IMNN 40.14
- Support Level
- CCTG $1.05
- IMNN $0.93
- Resistance Level
- CCTG $1.12
- IMNN $1.03
- Average True Range (ATR)
- CCTG 0.04
- IMNN 0.18
- MACD
- CCTG 0.01
- IMNN -0.10
- Stochastic Oscillator
- CCTG 46.67
- IMNN 1.39
About CCTG CCSC Technology International Holdings Limited
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas and Asia.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).